From October 25 to 27, JSC Grindeks will participate in the international exhibition “CPhI Worldwide 2011” in Messe Frankfurt, Germany. During the exhibition Grindeks will meet with its business partners as well as introduce visitors to its world class services and solutions. Grindeks exhibition stand will be placed in the Hall 4.2 with number 42B40.
Chairman of the Board of JSC Grindeks Jānis Romanovskis admits: “We will participate with a stand in this exhibition for the fourth consecutive year. It is the world’s leading pharmaceutical networking event, in which it is important to participate – to show that we are competitive among other pharmaceutical companies, to learn about the latest inventions, technologies and to stay informed about the latest pharmaceutical industry trends, and, of course, to use the advantages of the exhibition to meet with existing customers from all over the world and to build new business contacts. Experience from the previous years has shown that we are a stable participant of the global pharmaceutical market, we have our advantages and high-quality business solutions at affordable prices and we are assessed as a stable and reliable partner.”
In its exhibition stand Grindeks will promote cooperation in three main business fields:
1) Research, development, manufacturing and sales of Active pharmaceutical ingredients
2) Full service of contract-manufacturing of final dosage forms (FDF) – development of activities in performing FDF, validation of the manufacturing process and analysis methods, development of drug registration documentation and manufacturing of different technologies of FDF
3) Registration and marketing services including out-licensing, regulatory submissions, marketing authorization, translation, liaison, consulting, readability tests, as well as entire development of drug registration documents inCTD, eCTD in compliance with the EU and CIS countries requirements.
“CPhI Worldwide” is the world’s most important pharma event which offers opportunities for buyers, manufacturers, suppliers and users to exchange ideas, form alliances and do business with over 28,500 of their industry peers. “CPhI Worldwide” attracts tens of thousands of visitors from 140 countries
About Grindeks
Grindeks is the leading pharmaceutical company in the Baltic States. Its main fields of action are research, development, manufacturing and sale of original products, generics and active pharmaceutical ingredients. The Group consists of four subsidiary companies in Latvia, Estonia and Russia; representative offices in ten countries.
Grindeks specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups. The company`s product range consists of the combination of successful original products and generics,- it includes the original products Mildronate® and Ftorafur®, as well as more than 100 forms of effective and safe generics. Currently,Grindeks produces 16 active pharmaceutical ingredients.
Products of the company are exported to 50 countries and its export comprises more than 95% of the total turnover. The main sales markets are Russia and other CIS countries, the Baltic States, Germany and the Netherlands. In 2010, Grindeks, receiving the highest award from the Ministry of Economics of Latvia and the Latvian Investment and Development Agency, was recognized as the leading exporter of Latvia.
In order to increase productioncapacity and improve infrastructure,the company in recent years has implemented a series of large-scale investmentprojects, investing in thedevelopment 32.7 million lats within five years.
JSC Grindeks shares are listed in the Official List of “Nasdaq OMX Riga”. The major share holders of the JSC Grindeks are Kirovs Lipmans – 33.29%, Anna Lipmane – 16.69%, “Skandinaviska Enskilda Banken” – 12.42%, “AB.LV Private Equity fund 2010” – 11.38%, “Swedbank” AS Clients Account – 6.87%.
Further information:
Laila Klavina
Head of the Communications Department
JSC Grindeks
Phones: (+371) 67083370, (+371) 29256012
Fax: (+371) 67083505
E-mail: [email protected]
